IMPRESS

Immune Profiling of Cancer Patients via High-Resolution scRNA-Sequencing

The IMPRESS study aims to better understand why some people with non-small cell lung cancer (NSCLC) or triple-negative breast cancer (TNBC) respond to immunotherapy before surgery, while others do not. The study follows patients receiving neoadjuvant immunotherapy as part of their clinical care and compares the biological characteristics of patients with different treatment responses. By analysing blood and tumour tissue together with clinical and imaging data, researchers will investigate changes in the immune system and identify molecular markers associated with treatment response. The findings could help improve the prediction of treatment outcomes and contribute to the development of more personalised immunotherapy strategies for people with lung and breast cancer.

About the study

Recruiting

Patients, Healthy Volunteers 18+ years

Oncological diseases

Locations

Centre Hospitalier de Luxembourg – CHL Centre 4 rue Barblé
L-1210 Luxembourg

Centre Hospitalier Emile Mayrisch – Esch-sur-Alzette 1 rue Emile Mayrisch
L-4240 Esch-sur-Alzette

Luxembourg Research Clinic (LRC) 6, Rue Nicolas-Ernest Barblé,
L-1210 Luxembourg

Contact

For healthy volunteers: +352 26970400 and for patients: for further information or to take part in IMPRESS, please contact your oncologist directly.

Who can participate?

Eligible participants

You may be eligible to participate as a patient if you:

Adults (18 years of age or older) who provide a written informed consent.
Diagnosis of non-metastatic NSCLC or TNBC
Eligible to receive chemotherapy combined with an immune checkpoint inhibitor before surgery.

You may be eligible to participate as a healthy volunteer if you:

Adults (18 years of age or older) who provide a written informed consent.
No history of cancer.
Not pregnant.

Exclusion criteria

Exclusion criteria for patients:

Medical reason that prevents the patient from receiving the planned immunochemotherapy.
NSCLC with certain genetic alterations (EGFR mutations or ALK translocation).
Pregnant, planning to become pregnant, or breastfeeding.
Treatment with chemotherapy, targeted therapy, or radiotherapy within the previous 3 months.
Previous treatment with certain types of immunotherapy, including treatments targeting PD-1, PD-L1, PD-L2, or other specified immune pathways.
Vaccination with a live vaccine within 30 days before starting treatment.
Require certain doses of systemic corticosteroids or regularly use other immunosuppressive treatments.
Known history of HIV or an active hepatitis B or hepatitis C infection.

Not sure about eligibility?

The study team will review each case individually to determine eligibility. If you are unsure whether you are eligible, do not hesitate to contact us.

What will participants do?

The IMPRESS study includes patients with non-small cell lung cancer (NSCLC), patients with triple-negative breast cancer (TNBC), and a small group of healthy volunteers.

Participation in IMPRESS study does not require additional biopsies, surgery, or imaging beyond standard care.

Study procedures for patients:

01.

Health & Cancer History Review

The study team will collect relevant information about the patient’s health and cancer history, including medical history, treatments, laboratory results, imaging results, and response to treatment.

02.

Blood Sample Collection

Blood samples will be collected at two time points: before starting neoadjuvant immunochemotherapy, and after completing treatment but before surgery. Whenever possible, this will be done at the same time as routine blood tests.

03.

Tumour Tissue Collection

Archival or left-over tumour tissue, if available, will be collected from biopsies or surgery already performed as part of usual care. No additional biopsy or surgery is required for the study.

Study procedures for healthy volunteer:

01.

Attend one study visit

02.

Provide basic information

Provide basic information such as age, sex and smoking status,

03.

Allow one blood collection

Contact

For healthy volunteers: +352 26970400
For patients: for further information or to take part in IMPRESS, please contact your oncologist directly.